1. Adı ve Soyadı: Serdar DURDAĞI

2. Doğum Tarihi: 10/05/1978

3. Unvanı: Prof. Dr.

4. Öğrenim Durumu

Derece	Alan	Üniversite	Yıl
Lisans	Kimya	Hacettepe Üniversitesi	2001
Y. Lisans	Hesaplamalı Kimya	Bilkent Üniversitesi	2004
Doktora	Hesapsal Biyofizik ve Farmasötik Kimya	Freie Universität (FU) Berlin	2009

5. Akademik Ünvanlar

Yardımcı Doçentlik Tarihi: 22.10.2012
Doçentlik Tarihi: 17.05.2013
Profesörlük Tarihi: 01.10.2018

6. Yönetilen Yüksek Lisans ve Doktora Tezleri

6.1. Yüksek Lisans Tezleri

1. EHSAN SAYYAH (2023) Novel resistance-free ret tyrosine kinase inhibitor discovery through dynamic structure-based pharmacophore and qsar modeling and virtual screening of ultra large ligand libraries

2. SAFA HADDAD (2023) Developing novel hERG blocker models using heteroatom type and numbers from extensive ligand libraries

3. EZGİ SAMBUR (2023) Virtual screening of large-scale small molecule libraries against bruton tyrosine kinase effective in chronic lymphocytic leukaemia

4. HANEEN AMMURI (2022) Identification of Novel PARP1 Inhibitors based on Structural Similarities of FDA Approved Drugs.

5. İLAYDA TOLU (2022) In Silico Screening of the FDA and Peptidomimetics and Designing New Peptides against AXL-GAS6 Target

6. NTSOAKI BAITHEDI MOTAPANYANE (2022) Applications of Molecular Modelling Approaches fort he Identification of Novel SARS-CoV-2 RDRP Inhibitors

7. ZEYAD TAREQ JASIM ALABDULRAHEEM (2022) Ab initio and Comparative 3D Modeling of FAM222A and Target-Driven-Based Virtual Screening for the Identification of Novel Therapeutics

8. MD KAMRUL HASAN (2021) Molecular Mechanism of AT1R/PARP1 inhibitors interactions using combined molecular modeling approaches and physics-driven virtual identification of novel therapeutics against retinal inflammation

9. AYLA YILDIZ (2020) Determination of the effects of *Chrysophanol* on *pseudomans aeruginosa* quorum sensing mechanism and biofilm formation via in vitro and in silico methods

10. ASENA HİMMETOĞLU (2020) Machine learning algorithms and combined multi-scale molecular modeling simulations against NADPH oxidase (NOX) enzymes for designing of small molecule therapeutics

11. LALEHAN OKTAY (2020) Integrated ligand- and target-driven-based virtual screening studies for the identification of novel therapeutics against breast cancer

12. ARHUN ALİ BALKAN (2020) Investigation of anti-quorum sensing and anti-biofilm activities on *pseudomonas aeruginosa* of *peltigera* species by lichen and endolichenic fungus speciments in vitro and in silico methods

13. GURBET TUTUMLU (2019) Identification of novel hit molecules against B-cell leukemia/lymphoma-2 (BCL2)

14. VUSLAT ÖYKÜ SAYIN (2019) Structure-based drug design studies for the discovery of novel carbonic anhydrase IX-selective inhibitors

15. IŞIK KANTARCIOĞLU (2017) Discovery of novel AT1 inhibitors using computational methods

6.2. Doktora Tezleri

1. İSMAİL EROL (2023) Investigation of Oligomerization in Membrane Proteins by Computational Methods

2. HIND AL-JANABI (2022) Multiscale drug repurposing study fort he treatment of the Alzheimer's disease: A combined in silico and in vitro study

3. BUSECAN AKSOYDAN (2021) An integrated molecular modeling approaches for the novel therapeutics by using cytosolic and memnrane-bound target proteins as model systems

3. GÜLŞAH AYDIN (2020) Identification of p53-MDM2 potential inhibitors with virtual screening and multidimensional molecular modeling inhibitors

4. YUSUF SERHAT İŞ (2019) Design of monoamine oxidase enzyme (MAO) inhibitors play important role in the treatment of neurodegenerative diseases using computer aided methods

5. GÜLRU KAYIK (2017) In silico design of hERG non-blocker compounds with retained pharmacological activity using multi-scale molecular modeling applications

6. RAMİN EKHTEIARI SALMAS (2015) Multi-scale modeling and investigation of activation mechanisms of G protein-coupled receptors

7. Yayınlar

7.1. Uluslararası hakemli dergilerde yayınlanan makaleler (SCI & SSCI & Arts and Humanities)

1. Sukkar B., Oktay, L., Sahaboglu A., Moayedi A., Zenouri S., Tamer Al-Maghout, Cantó, A., Miranda M., **Durdagi, S**., Hosseinzadeh Z. Inhibition of altered Orai1 channel in Müller cells rescues Photoreceptor in degenerated retina. ***Glia*** 2023 (accepted)

2. Tunc H, Dogan B, Darendeli Kiraz BN, Sari M, **Durdagi S,** Kotil S. Prediction of HIV-1 protease resistance using genotypic, phenotypic, and molecular information with artificial neural networks (2023) ***PeerJ.*** 2023;11:e14987. doi: 10.7717/peerj.14987.

3. Atalay, N., Akcan, EK., Gul, M., Ayan, E., Destan, E., Ertem, FB., Tokay, N., Cakilkaya, B., Nergiz, Z., Karakadioglu, G., Kepceoglu, A., Yapici, I., Tosun, B., Baldir, N., Yildirim, G., Johnson, JA., Guven, O., Shafiei, A., Arslan, NE., Yilmaz, M., Kulakman, C., Paydos, SS., Cinal, ZS., Sabanoglu, K., Aysegul, P., Yilmaz, A., Canbay, B., Asci, B., Kartal, E.; Tavli, S., Caliseki, M., Goc, G.; Mermer, A., Yesilay, G., Altuntas, S, Tateishi, H., Otsuka, M., Fujita, M., Tekin, S., Ciftci, H., **Durdagi, S**., Doganay, GD., Karaca, E. Turkoz, BK., Kabasakal, BV., Kati, A., Demirci, H. Cryogenic X-ray crystallographic studies of biomacromolecules at Turkish Light Source "Turkish DeLight" (2023) ***Turk. Journal of Biology*** 47(1), pp. 1-13.

4. Calis, S., Dogan, B., **Durdagi, S**., Celebi, A., Yapicier, O., Kilic, T., Turanli, E.T., Avsar, T. A novel BH3 mimetic Bcl-2 inhibitor promotes autophagic cell death and reduces in vivo Glioblastoma tumor growth (2022) ***Cell Death Discovery*** *8*(1), p.433.

5. Erol, I., Kotil, S. E., Ortakci, F., **Durdagi, S**. Exploring the binding capacity of lactic acid bacteria derived bacteriocins against RBD of SARS-CoV-2 Omicron variant by molecular simulations (2022) ***Journal of Biomolecular Structure and Dynamics*** 1-11. DOI: 10.1080/07391102.2022.2158934

6. Doğan, N., Yavuz, S.Ç., Sahin, K., Orhan, M.D., Kekeçmuhammed, H., Calis, S., Küp, F.Ö., Avsar, T., Akkoc, S., Tapera, M., Sahin, O., Kilic, T., **Durdagi, S.,** Saripinar, E. Synthesis, Characterization, Biological Activity and Molecular Modeling Studies of Novel Aminoguanidine Derivatives (2022) ***ChemistrySelect*** *7*(45), p.e202202819.

7. Tapera, M., Kekeçmuhammed, H., Sahin, K., Krishna, V.S., Lherbet, C., Homberset, H., Chebaiki, M., Tønjum, T., Mourey, L., Zorlu, Y., **Durdagi, S.** Synthesis, characterization, anti-tuberculosis activity and molecular modeling studies of thiourea derivatives bearing aminoguanidine moiety (2022) ***Journal of Molecular Structure*** *1270*, p.133899.

8. Aksoydan, B., **Durdagi, S**. Virtual drug repurposing study for the CGRPR identifies pentagastrin and leuprorelin as putative candidates (2022) ***Journal of Molecular Graphics and Modelling*** *116*, pp. 108254.

9. Onder, F.C., Siyah, P., **Durdagi, S**., Ay, M., Ozpolat, B. Novel etodolac derivatives as eukaryotic elongation factor 2 kinase (eEF2K) inhibitors for targeted cancer therapy (2022) ***RSC Medicinal Chemistry*** 13(7), pp.840-849.

10. Onder, F.C., Sahin, K., Senturk, M., **Durdagi, S**., Ay, M. Identifying highly effective coumarin-based novel cholinesterase inhibitors by in silico and in vitro studies (2022) ***Journal of Molecular Graphics and Modelling*** 115, p.108210.

11. Sucu, B.O., Koc, E.B., Ipek, O.S., Mirat, A., Almas, F., Guzel, M.A., Dogan, B., Uludag, D., Karakas, N., **Durdagi, S**., Guzel, M. Design and synthesis of novel caffeic acid phenethyl ester (CAPE) derivatives and their biological activity studies in glioblastoma multiforme (GBM) cancer cell lines (2022) ***Journal of Molecular Graphics and Modelling*** 113, p.108160.

12. Zaka, M., Mohammed, F., Fareed, A. F., **Durdagi, S.** Development of deep learning based QSAR models for the identification of novel anti-cancer therapeutics against malignant glioma from ultra large libraries (2022). ***Biophysical Journal*** 121(3), 529a.

13. **Durdagi, S**., Avsar, T., Orhan, M.D., Serhatli, M., Balcioglu, B.K., Ozturk, H.U., Kayabolen, A., Cetin, Y., Aydinlik, S., Bagci-Onder, T., Tekin, S. The neutralization effect of montelukast on SARS-CoV-2 is shown by multiscale in silico simulations and combined in vitro studies (2022) ***Molecular Therapy*** 30(2), pp.963-974.

14. Cetin, Y., Aydinlik, S., Gungor, A., Kan, T., Avsar, T., **Durdagi, S**. Review on in silico methods, high-throughput screening techniques, and cell culture based in vitro assays for SARS-CoV-2 (2022) ***Current Medicinal Chemistry*** 29(38), pp.5925-5948.

15. Mansoor, S., Kayik, G.; **Durdagi, S**.; Sensoy, O. Mechanistic insight into the impact of a bivalent ligand on the structure and dynamics of a GPCR oligomer (2022) ***Computational and Structural Biotechnology Journal*** 20, pp. 925-936.

16. Aksoydan, B., **Durdagi, S.** Molecular simulations reveal the impact of RAMP1 on ligand binding and dynamics of calcitonin gene-related peptide receptor heterodimer (2022) ***Computers in Biology and Medicine*** 141 pp. 105130.

17. **Durdagi, S**., Avsar, T., Orhan, MD., Serhatli, M., Balcioglu, B.K., Ozturk, H.U., Kayabolen, A., Cetin, Y., Aydinlik, S., Bagci-Onder, T., Tekin, S., Demirci, H., Guzel, M., Akdemir, A., Calis, S., Oktay, L., Tolu, I., Butun, Y.E., Erdemoglu, C., Olkan, A., Tokay, N., Isik, S., Ozcan, A., Acar, E., Buyukkilic, S., Yumak, Y. The neutralization effect of Montelukast on SARS-CoV-2 is shown by multiscale in silico simulations and combined in vitro studies (2022) ***Molecular Therapy*** 30(2), pp.963-974.

18. Balli, OI., Uversky, VN., **Durdagi, S**., Coskuner-Weber, O. Challenges and limitations in the studies of glycoproteins: A computational chemist's perspective (2022) ***Proteins - Structure Function and Bioinformatics*** 90(2), pp322-339.

19. Bayrak, C., Yildizhan, G., Kilinc, N., **Durdagi, S.,** Menzek, A. Synthesis and aldose reductase inhibition effects of novel N-benzyl-4-methoxyaniline derivatives (2021) ***Chemistry and Biodiversity*** 19(1):e202100530.

20. Dogan, K., Erol, E., Orhan, MD., Degirmenci, Z., Kan, T., Gungor, A., Yasa, B. Avsar, T., Cetin, Y., **Durdagi, S**., Guzel, M. Instant determination of the artemisinin from various Artemisia annua L. extracts by LC-ESI-MS/MS and their in-silico modelling and in vitro antiviral activity studies against SARS-CoV-2 (2022) ***Phytochemical Analysis***, 33(2), pp303-319.

21. **Durdagi, S.,** Orhan, MD., Aksoydan, B., Calis, S., Dogan, B., Sahin, K., Shahraki, A., Iyison, NB., Avsar, T. Screening of Clinically Approved and Investigation Drugs as Potential Inhibitors of SARS-CoV-2: A Combined in silico and in vitro Study (2022) ***Molecular Informatics*** DOI: 10.1002/minf.202100062

22. Sucu, B.O., Koc, E.B., Savlug, O., Mirat, A., Almas, F., Guzel, M.A., Dogan, B., Uludag, D., Karakas, N., **Durdagi, S**., Guzel, M. Synthesis of Novel Caffeic Acid Phenethyl Ester (CAPE) Derivatives and Their Biological Activity Studies in Glioblastoma Multiforme (GBM) Cancer Cell Lines (2021) ***Journal of Molecular Graphics and Modelling*** 113, pp.108160.

23. Guven, O., Gul, M., Ayan, E., Gocenler O., Buyukdag, C., Johnson, J.A., Cakilkaya, B., Usta, G., Ertem, F.B., Tokay, N., Yuksel, B., Botha S. Ketewala, G., Su, Z., Hayes, B., Poitevin, F., Yoon, C.H., Kupitz, C., **Durdagi, S**., Sierra, R.G., Demirci, H. Case Study of High Throughput Drug Screening and Remote Data Collection for SARS-CoV-2 Main Protease by Using Serial Femtosecond X-ray Crystallography (2021) ***Crystals*** 11(12), pp.1579.

24. **Durdagi S,** Dağ Ç, Dogan B, Yigin M, Avsar T, Buyukdag C, Erol I, Ertem FB, Calis S, Yildirim G, Orhan MD, Guven O, Aksoydan B, Destan E, Sahin K, Besler SO, Oktay L, Shafiei A, Tolu I, Ayan E, Yuksel B, Peksen AB, Gocenler O, Yucel AD, Can O, Ozabrahamyan S, Olkan A, Erdemoglu E, Aksit F, Tanisali G, Yefanov OM, Barty A, Tolstikova A, Ketawala GK, Botha S, Dao EH, Hayes B, Liang M, Seaberg MH, Hunter MS, Batyuk A, Mariani V, Su Z, Poitevin F, Yoon CH, Kupitz C, Sierra RG, Snell EH, DeMirci H. Near-physiological-temperature serial crystallography reveals conformations of SARS-CoV-2 main protease active site for improved drug repurposing (2021) ***Structure*** 29(12), pp.1382-1396.e6. doi: 10.1016/j.str.2021.07.007.

25. Oguz, M., Dogan, B., **Durdagi, S.**, Bhatti, AA., Karakurt, S., Yilmaz, M. In vitro Cytotoxic Assay and Numerical Investigation of Inclusion Complex of Calix[4,8]arene and Quercetin (2021) ***New Journal of Chemistry*** **45**, pp18443-18452.

26. Sahin, K., Saripinar, E., **Durdagi, S.** Determination of Bioactive Pharmacophore Groups in Isatin Derivatives with Combined 4D-QSAR and Target-driven Approaches (2021) ***SAR and QSAR Environmental Research*** DOI: 10.1080/1062936X.2021.1971760.

27. Ozten O, Zengin Kurt B, Sonmez F, Dogan B, **Durdagi S.** Synthesis, molecular docking and molecular dynamics studies of novel tacrine-carbamate derivatives as potent cholinesterase inhibitors (2021) ***Bioorg Chem***. 115:105225. doi: 10.1016/j.bioorg.2021.105225.

28. Oktay, L., Erdemoglu, E., Tolu, I., Yumak, Y., Ozcan, A., Acar, E., Buyukkilic, S., Olkan, A., **Durdagi, S.** Binary-QSAR guided virtual screening of FDA approved drugs and compounds in clinical investigation against SARS-CoV-2 main protease (2021) ***Turk. J. Biol***. 45, pp459-468.

29. Erol, I., Fidan, O., Yetiman, A., Kotil, E., **Durdagi, S.,** Ortakci, F. In Silico Analysis of Bacteriocins from Lactic Acid Bacteria Against SARS-CoV-2 (2021) ***Probiotics and Antimicrobial Proteins*** DOI: 10.1007/s12602-021-09879-0.

30. Kanan, T., Kanan, D., Jaffar, I., **Durdagi, S.** Transcription Factor NF-κB as Target for SARS-CoV-2 Drug Discovery Efforts Using Inflammation-based QSAR Screening Model (2021) ***Journal of Molecular Graphics and Modelling*** 108, pp107968.

31. Siyah, P., Akgol, S., **Durdagi, S.,** Kocabas, F. Identification of first-in-class plasmodium OTU inhibitors with potent anti-malarial activity (2021) ***Biochemical Journal*** 478 (18), pp3445–3466.

32. Güngör, T., Ozleyen, A., Yılmaz, Y.B., Siyah, P., Ay, M., **Durdagi, S.,** Tumer, T.B. New nimesulide derivatives with amide/sulfonamide moieties: Selective COX-2 inhibition and antitumor effects (2021) ***European Journal of Medicinal Chemistry***, 221, DOI: 10.1016/j.ejmech.2021.113566.

33. Ikram, S., Ahmad, F., Ahmad, J., **Durdagi, S**. Screening of small molecule libraries using combined text mining, ligand- and target-driven based approaches for identification of novel granzyme H inhibitors (2021) ***Journal of Molecular Graphics and Modelling***, 105, DOI: 10.1016/j.jmgm.2021.107876

34. Onder, F.C, Kahraman, N., Bellur Atici, E., Cagir, A., Kandemir, H., Tatar, G., Taskin Tok, T., Kara, G., Karliga, B., **Durdagi, S**., Ay, M., Ozpolat, B. Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth in Vivo (2021) ***ACS Pharmacology and Translational Science***, 4 (2), pp. 926-940.

35. Shahraki, A., Işbilir, A., Dogan, B., Lohse, M.J., **Durdagi, S.,** Birgul-Iyison, N. Structural and Functional Characterization of Allatostatin Receptor Type-C of Thaumetopoea pityocampa, a Potential Target for Next-Generation Pest Control Agents (2021) ***Journal of Chemical Information and Modeling***, 61 (2), pp. 715-728.

36. Kanan, D., Kanan, T., Dogan, B., Orhan, M.D., Avsar, T., **Durdagi, S**. An Integrated in silico Approach and in vitro Study for the Discovery of Small-Molecule USP7 Inhibitors as Potential Cancer Therapies (2021) ***ChemMedChem***, 16 (3), pp. 555-567.

37. Dogan, B., **Durdagi, S**. Drug Re-positioning Studies for Novel HIV-1 Inhibitors Using Binary QSAR Models and Multi-target-driven In Silico Studies (2021) ***Molecular Informatics***, 40 (2), DOI: 10.1002/minf.202000012

38. Akbayrak, I.Y., Caglayan, S.I., **Durdagi, S.,** Kurgan, L., Uversky, V.N., Ulver, B., Dervisoğlu, H., Haklidir, M., Hasekioglu, O., Coskuner-Weber, O. Structures of MERS-CoV macro domain in aqueous solution with dynamics: Impacts of parallel tempering simulation techniques and CHARMM36m and AMBER99SB force field parameters (2021) ***Proteins: Structure, Function and Bioinformatics***, DOI: 10.1002/prot.26150

39. Sahin, K., Orhan, M.D., Avsar, T., **Durdagi, S.** Hybrid in Silico and TR-FRET-Guided Discovery of Novel BCL-2 Inhibitors (2021) ***ACS Pharmacology and Translational Science***, DOI: 10.1021/acsptsci.0c00210

40. Sahin, K., **Durdagi, S.** Identifying new piperazine-based PARP1 inhibitors using text mining and integrated molecular modeling approaches (2021) ***Journal of Biomolecular Structure and Dynamics***, 39 (2), pp. 681-690.

41. Onder, FC., **Durdagi, S.,** Kahraman, N., Uslu, TN., Kandemir, H., Atici, EB., Ozpolat, B., Ay, M. Novel inhibitors of eukaryotic elongation factor 2 kinase: In silico, synthesis and in vitro studies (2021) ***Bioorganic Chemistry,*** DOI: 10.1016/j.bioorg.2021.105296

42. Avsar, T., Yigit, BN., Turan, G., Altunsu, D., Calis, S., Kurt, B., Kilic, T., Ergun, MY., **Durdagi, S**., Acar, M. Development of imidazolone based angiotensin II receptor type I inhibitor small molecule as a chemotherapeutic agent for cell cycle inhibition (2021) ***All Life***, 14(1), pp678-690.

43. Ikram, S., Ahmad, J., Rehman, I.-U., **Durdagi, S.** Potent novel inhibitors against hepatitis C virus NS3 (HCV NS3 GT-3a) protease domain (2020) ***Journal of Molecular Graphics and Modelling***, 101, DOI: 10.1016/j.jmgm.2020.107727

44. Ahmad, J., Ikram, S., Hafeez, A.B., **Durdagi, S.** Physics-driven identification of clinically approved and investigation drugs against human neutrophil serine protease 4 (NSP4): A virtual drug repurposing study (2020) ***Journal of Molecular Graphics and Modelling***, 101, DOI: 10.1016/j.jmgm.2020.107744

45. Birgul Iyison, N., Sinmaz, M.G., Duan Sahbaz, B., Shahraki, A., Aksoydan, B., **Durdagi, S.** In silico characterization of adipokinetic hormone receptor and screening for pesticide candidates against stick insect, Carausius morosus (2020) ***Journal of Molecular Graphics and Modelling***, 101, DOI: 10.1016/j.jmgm.2020.107720

46. Turan, R.D., Albayrak, E., Uslu, M., Siyah, P., Alyazici, L.Y., Kalkan, B.M., Aslan, G.S., Yucel, D., Aksoz, M., Tuysuz, E.C., Meric, N., **Durdagi, S**., Gulbas, Z., Kocabas, F. Development of Small Molecule MEIS Inhibitors that modulate HSC activity (2020) ***Scientific Reports***, 10 (1), art. no. 7994, DOI: 10.1038/s41598-020-64888-3

47. Kulabas, S.S., Onder, F.C., Yılmaz, Y.B., Ozleyen, A., **Durdagi, S**., Sahin, K., Ay, M., Tumer, T.B. In vitro and in silico studies of nitrobenzamide derivatives as potential anti-neuroinflammatory agents (2020) ***Journal of Biomolecular Structure and Dynamics*,** 38 (15), pp. 4655-4668.

48. Oguz, M., Bhatti, A.A., Dogan, B., Karakurt, S., **Durdagi, S**., Yilmaz, M. Formation of the inclusion complex of water soluble fluorescent calix[4]arene and naringenin: solubility, cytotoxic effect and molecular modeling studies (2020) ***Journal of Biomolecular Structure and Dynamics***, 38 (13), pp. 3801-3813.

49. Is, Y.S., Aksoydan, B., Senturk, M., Yurtsever, M., **Durdagi, S.** Integrated Binary QSAR-Driven Virtual Screening and in Vitro Studies for Finding Novel hMAO-B-Selective Inhibitors (2020) ***Journal of Chemical Information and Modeling***, 60 (8), pp. 4047-4055.

50. Sahin, K., Zengin Kurt, B., Sonmez, F., **Durdagi, S.** Novel AChE and BChE inhibitors using combined virtual screening, text mining and in vitro binding assays (2020) ***Journal of Biomolecular Structure and Dynamics***, 38 (11), pp. 3342-3358.

51. Aydin, G., Paksoy, M.N., Orhan, M.D., Avsar, T., Yurtsever, M., **Durdagi, S.** Proposing novel MDM2 inhibitors: Combined physics-driven high-throughput virtual screening and in vitro studies (2020) ***Chemical Biology and Drug Design***, 96 (1), pp. 684-700.

52. Sahaboglu, A., Miranda, M., Canjuga, D., Avci-Adali, M., Savytska, N., Secer, E., Feria-Pliego, J.A., Kayık, G., **Durdagi, S.** Drug repurposing studies of PARP inhibitors as a new therapy for inherited retinal degeneration (2020) ***Cellular and Molecular Life Sciences***, 77 (11), pp. 2199-2216.

53. Gunay, B.C., Yurtsever, M., **Durdagi, S.** Elucidation of interaction mechanism of hERG1 potassium channel with scorpion toxins BeKm-1 and BmTx3b (2020) ***Journal of Molecular Graphics and Modelling***, 96, DOI: 10.1016/j.jmgm.2019.107504

54. Tutumlu, G., Dogan, B., Avsar, T., Orhan, M.D., Calis, S., **Durdagi, S**. Integrating Ligand and Target-Driven Based Virtual Screening Approaches With in vitro Human Cell Line Models and Time-Resolved Fluorescence Resonance Energy Transfer Assay to Identify Novel Hit Compounds Against BCL-2 (2020) ***Frontiers in Chemistry***, 8, DOI: 10.3389/fchem.2020.00167

55. Comert Onder, F., **Durdagi, S.,** Sahin, K., Ozpolat, B., Ay, M. Design, Synthesis, and Molecular Modeling Studies of Novel Coumarin Carboxamide Derivatives as eEF-2K Inhibitors (2020) ***Journal of Chemical Information and Modeling***, 60 (3), pp. 1766-1778.

56. Ikram, S., Ahmad, J., **Durdagi, S.** Screening of FDA approved drugs for finding potential inhibitors against Granzyme B as a potent drug-repurposing target (2020) ***Journal of Molecular Graphics and Modelling***, 95, DOI: 10.1016/j.jmgm.2019.107462

57. Zengin Kurt, B., **Durdagi, S**., Celebi, G., Ekhteiari Salmas, R., Sonmez, F. Synthesis, anticholinesterase activity and molecular modeling studies of novel carvacrol-substituted amide derivatives (2020) ***Journal of Biomolecular Structure and Dynamics***, 38 (3), pp. 841-859.

58. Kuskucu, M., Akyildiz, V., Kulmány, Á., Ergün, Y., Zencir, S., Zupko, I., **Durdagi, S**., Zaka, M., Sahin, K., Orhan, H., Topcu, Z. Structural modification of ellipticine derivatives with alkyl groups of varying length is influential on their effects on human DNA topoisomerase II: a combined experimental and computational study (2020) ***Medicinal Chemistry Research***, 29 (2), pp. 189-198.

59. Zaka, M., Abbasi, B.H., **Durdagi, S**. Novel tumor necrosis factor-α (TNF-α) inhibitors from small molecule library screening for their therapeutic activity profiles against rheumatoid arthritis using target-driven approaches and binary QSAR models (2019) ***Journal of Biomolecular Structure and Dynamics***, 37 (9), pp. 2464-2476.

60. Kurt, B.Z., Dag, A., Doğan, B., **Durdagi, S**., Angeli, A., Nocentini, A., Supuran, C.T., Sonmez, F. Synthesis, biological activity and multiscale molecular modeling studies of bis-coumarins as selective carbonic anhydrase IX and XII inhibitors with effective cytotoxicity against hepatocellular carcinoma (2019) ***Bioorganic Chemistry***, 87, pp. 838-850.

61. **Durdagi, S.,** Erol, I., Salmas, R.E., Aksoydan, B., Kantarcioglu, I. Oligomerization and cooperativity in GPCRs from the perspective of the angiotensin AT1 and dopamine D2 receptors (2019) ***Neuroscience Letters***, 700, pp. 30-37.

62. **Durdagi, S**., Dogan, B., Erol, I., Kayık, G., Aksoydan, B. Current status of multiscale simulations on GPCRs (2019*)* ***Current Opinion in Structural Biology***, 55, pp. 93-103.

63. Ntountaniotis, D., Andreadelis, I., Kellici, T.F., Karageorgos, V., Leonis, G., Christodoulou, E., Kiriakidi, S., Becker-Baldus, J., Stylos, E.K., Chatziathanasiadou, M.V., Chatzigiannis, C.M., Damalas, D.E., Aksoydan, B., Javornik, U., Valsami, G., Glaubitz, C., **Durdagi, S**., Thomaidis, N.S., Kolocouris, A., Plavec, J., Tzakos, A.G., Liapakis, G., Mavromoustakos, T. Host-Guest Interactions between Candesartan and Its Prodrug Candesartan Cilexetil in Complex with 2-Hydroxypropyl-β-cyclodextrin: On the Biological Potency for Angiotensin II Antagonism (2019) ***Molecular Pharmaceutics***, 16 (3), pp. 1255-1271.

64. Orhan, I.E., Senol Deniz, F.S., Salmas, R.E., **Durdagi, S**., Epifano, F., Genovese, S., Fiorito, S. Combined molecular modeling and cholinesterase inhibition studies on some natural and semisynthetic O-alkylcoumarin derivatives (2019) ***Bioorganic Chemistry***, 84, pp. 355-362.

65. Mollica, A., Zengin, G., **Durdagi, S**., Ekhteiari Salmas, R., Macedonio, G., Stefanucci, A., Dimmito, M.P., Novellino, E. Combinatorial peptide library screening for discovery of diverse α-glucosidase inhibitors using molecular dynamics simulations and binary QSAR models (2019) ***Journal of Biomolecular Structure and Dynamics***, 37 (3), pp. 726-740.

66. Erol, I., Cosut, B., **Durdagi, S.** Toward Understanding the Impact of Dimerization Interfaces in Angiotensin II Type 1 Receptor (2019) ***Journal of Chemical Information and Modeling***, DOI: 10.1021/acs.jcim.9b00294

67. Kiriakidi, S., Kolocouris, A., Liapakis, G., Ikram, S., **Durdagi, S.,** Mavromoustakos, T. Effects of cholesterol on GPCR function: Insights from computational and experimental studies (2019) ***Advances in Experimental Medicine and Biology***, 1135, pp. 89-103.

68. Cavdar, H., Senturk, M., Guney, M., **Durdagi, S**., Kayik, G., Supuran, C.T., Ekinci, D. Inhibition of acetylcholinesterase and butyrylcholinesterase with uracil derivatives: kinetic and computational studies (2019) ***Journal of Enzyme Inhibition and Medicinal Chemistry***, 34 (1), pp. 429-437.

69. Kanan, T., Kanan, D., Erol, I., Yazdi, S., Stein, M., **Durdagi, S.** Targeting the NF-κB/IκBα complex via fragment-based E-Pharmacophore virtual screening and binary QSAR models (2019) ***Journal of Molecular Graphics and Modelling*,** 86, pp. 264-277.

70. **Durdagi, S**., Tahir ul Qamar, M., Salmas, R.E., Tariq, Q., Anwar, F., Ashfaq, U.A. Investigating the molecular mechanism of staphylococcal DNA gyrase inhibitors: A combined ligand-based and structure-based resources pipeline (2018) ***Journal of Molecular Graphics and Modelling****,* 85, pp. 122-129.

71. Zaka, M., Abbasi, B.H., **Durdagi, S**. Proposing novel TNFα direct inhibitor Scaffolds using fragment-docking based e-pharmacophore modeling and binary QSAR-based virtual screening protocols pipeline (2018) ***Journal of Molecular Graphics and Modelling*****,** 85, pp. 111-121.

72. Ekhteiari Salmas, R., Serhat Is, Y., **Durdagi, S**., Stein, M., Yurtsever, M. A QM protein–ligand investigation of antipsychotic drugs with the dopamine D2 Receptor (D2R) (2018) ***Journal of Biomolecular Structure and Dynamics*****,** 36 (10), pp. 2668-2677.

73. Is, Y.S., **Durdagi, S.,** Aksoydan, B., Yurtsever, M. Proposing Novel MAO-B Hit Inhibitors Using Multidimensional Molecular Modeling Approaches and Application of Binary QSAR Models for Prediction of Their Therapeutic Activity, Pharmacokinetic and Toxicity Properties (2018) ***ACS Chemical Neuroscience***, 9 (7), pp. 1768-1782.

74. Salmas, R.E., Seeman, P., Stein, M., **Durdagi, S.** Structural Investigation of the Dopamine-2 Receptor Agonist Bromocriptine Binding to Dimeric D2HighR and D2LowR States (2018) ***Journal of Chemical Information and Modeling***, 58 (4), pp. 826-836.

75. Orhan, I.E., Jedrejek, D., Senol, F.S., Salmas, R.E., **Durdagi, S**., Kowalska, I., Pecio, L., Oleszek, W. Molecular modeling and in vitro approaches towards cholinesterase inhibitory effect of some natural xanthohumol, naringenin, and acyl phloroglucinol derivatives (2018) ***Phytomedicine*****,** 42, pp. 25-33.

76. Erdemli, M.E., Ekhteiari Salmas, R., **Durdagi, S.,** Akgul, H., Demirkol, M., Aksungur, Z., Selamoglu, Z. Biochemical changes induced by grape seed extract and low level laser therapy administration during intraoral wound healing in rat liver: an experimental and in silico study (2018) ***Journal of Biomolecular Structure and Dynamics***, 36 (4), pp. 993-1008.

77. Ekhteiari Salmas, R., **Durdagi, S**., Gulhan, M.F., Duruyurek, M., Abdullah, H.I., Selamoglu, Z. The effects of pollen, propolis, and caffeic acid phenethyl ester on tyrosine hydroxylase activity and total RNA levels in hypertensive rats caused by nitric oxide synthase inhibition: experimental, docking and molecular dynamic studies (2018) ***Journal of Biomolecular Structure and Dynamics***, 36 (3), pp. 609-620.

78. **Durdagi, S.,** Aksoydan, B., Erol, I., Kantarcioglu, I., Ergun, Y., Bulut, G., Acar, M., Avsar, T., Liapakis, G., Karageorgos, V., Salmas, R.E., Sergi, B., Alkhatib, S., Turan, G., Yigit, B.N., Cantasir, K., Kurt, B., Kilic, T. Integration of multi-scale molecular modeling approaches with experiments for the in silico guided design and discovery of novel hERG-Neutral antihypertensive oxazalone and imidazolone derivatives and analysis of their potential restrictive effects on cell proliferation (2018) ***European Journal of Medicinal Chemistry***, 145, pp. 273-290.

79. Erol, I., Aksoydan, B., Kantarcioglu, I., **Durdagi, S.** Application of multiscale simulation tools on GPCRs. An example with angiotensin II type 1 receptor (2018) ***Methods in Molecular Biology***, 1824, pp. 431-448.

80. Aksoydan, B., Kantarcioglu, I., Erol, I., Salmas, R.E., **Durdagi, S.** Structure-based design of hERG-neutral antihypertensive oxazalone and imidazolone derivatives (2018) ***Journal of Molecular Graphics and Modelling***, 79, pp. 103-117.

81. Mirza, S.B., Lee, R.C.H., Chu, J.J.H., Salmas, R.E., Mavromoustakos, T**., Durdagi, S.** Discovery of selective dengue virus inhibitors using combination of molecular fingerprint-based virtual screening protocols, structure-based pharmacophore model development,

molecular dynamics simulations and in vitro studies (2018) ***Journal of Molecular Graphics and Modelling***, 79, pp. 88-102.

82. Rodrigues, M.J., Slusarczyk, S., Pecio, Ł., Matkowski, A., Salmas, R.E., **Durdagi, S.,** Pereira, C., Varela, J., Barreira, L., Custódio, L. In vitro and in silico approaches to appraise Polygonum maritimum L. as a source of innovative products with anti-ageing potential (2018**)** ***Industrial Crops and Products***, 111, pp. 391-399.

83. Kayık, G., Tüzün, N.Ş., **Durdagi, S.** In silico design of novel hERG-neutral sildenafil-like PDE5 inhibitors (2017) ***Journal of Biomolecular Structure and Dynamics***, 35 (13), pp. 2830-2852.

84. Kayık, G., Tüzün, N.Ş., **Durdagi, S.** Structural investigation of vesnarinone at the pore domains of open and open-inactivated states of hERG1 K+ channel (2017) ***Journal of Molecular Graphics and Modelling***, 77, pp. 399-412.

85. Aksoydan, B., Kantarcioglu, I., Erol, I., Salmas, R.E., **Durdagi, S.** Structure-based design of hERG-neutral antihypertensive oxazalone and imidazolone derivatives (2017) ***Journal of Molecular Graphics and Modelling***, 77, pp. 240-249.

86. Mirza, S.B., Lee, R.C.H., Chu, J.J.H., Salmas, R.E., Mavromoustakos, T., **Durdagi, S**. Discovery of selective dengue virus inhibitors using combination of molecular fingerprint-based virtual screening protocols, structure-based pharmacophore model development, molecular dynamics simulations and in vitro studies (2017) ***Journal of Molecular Graphics and Modelling***, 77, p. 338.

87. Akıncıoğlu, A., Kocaman, E., Akıncıoğlu, H., Salmas, R.E., **Durdagi, S.,** Gülçin, İ., Supuran, C.T., Göksu, S. The synthesis of novel sulfamides derived from β-benzylphenethylamines as acetylcholinesterase, butyrylcholinesterase and carbonic anhydrase enzymes inhibitors (2017) ***Bioorganic Chemistry***, 74, pp. 238-250.

88. Salmas, R.E., Gulhan, M.F., **Durdagi, S**., Sahna, E., Abdullah, H.I., Selamoglu, Z. Effects of propolis, caffeic acid phenethyl ester, and pollen on renal injury in hypertensive rat: An experimental and theoretical approach (2017) ***Cell Biochemistry and Function***, 35 (6), pp. 304-314.

89. Salmas, R.E., Stein, M., Yurtsever, M., Seeman, P., Erol, I., Mestanoglu, M., **Durdagi, S.** The signaling pathway of dopamine D2 receptor (D2R) activation using normal mode analysis (NMA) and the construction of pharmacophore models for D2R ligands (2017) ***Journal of Biomolecular Structure and Dynamics***, 35 (9), pp. 2040-2048.

90. Ekhteiari Salmas, R., Unlu, A., Bektaş, M., Yurtsever, M., Mestanoglu, M., **Durdagi, S.** Virtual screening of small molecules databases for discovery of novel PARP-1 inhibitors: combination of in silico and in vitro studies (2017) ***Journal of Biomolecular Structure and Dynamics***, 35 (9), pp. 1899-1915.

91. Salmas, R.E., Seeman, P., Aksoydan, B., Erol, I., Kantarcioglu, I., Stein, M., Yurtsever, M., **Durdagi, S.** Analysis of the Glutamate Agonist LY404,039 Binding to Nonstatic Dopamine Receptor D2 Dimer Structures and Consensus Docking (2017) ***ACS Chemical Neuroscience***, 8 (6), pp. 1404-1415.

92. **Durdagi, S**., Erol, I., Salmas, R.E., Patterson, M., Noskov, S.Y. First universal pharmacophore model for hERG1 K+ channel activators: acthER (2017) ***Journal of Molecular Graphics and Modelling***, 74, pp. 153-170.

93. Erol, I., Aksoydan, B., Kantarcioglu, I., Salmas, R.E., **Durdagi, S.** Identification of novel serotonin reuptake inhibitors targeting central and allosteric binding sites: A virtual screening and molecular dynamics simulations study (2017) ***Journal of Molecular Graphics and Modelling***, 74, pp. 193-202.

94. Ekhteiari Salmas, R., Seeman, P., Aksoydan, B., Stein, M., Yurtsever, M., **Durdagi, S.** Biological Insights of the Dopaminergic Stabilizer ACR16 at the Binding Pocket of Dopamine D2 Receptor (2017) ***ACS Chemical Neuroscience***, 8 (4), pp. 826-836.

95. Shityakov, S., Salmas, R.E., **Durdagi, S.,** Roewer, N., Förster, C., Broscheit, J. Solubility profiles, hydration and desolvation of curcumin complexed with γ-cyclodextrin and hydroxypropyl-γ-cyclodextrin (2017) ***Journal of Molecular Structure***, 1134, pp. 91-98.

96. Salmas, R.E., Yurtsever, M., **Durdagi, S.** Atomistic molecular dynamics simulations of typical and atypical antipsychotic drugs at the dopamine D2 receptor (D2R) elucidates their inhibition mechanism (2017) ***Journal of Biomolecular Structure and Dynamics***, 35 (4), pp. 738-754.

97. Mirza, S.B., Ekhteiari Salmas, R., Fatmi, M.Q., **Durdagi, S.** Discovery of Klotho peptide antagonists against Wnt3 and Wnt3a target proteins using combination of protein engineering, protein–protein docking, peptide docking and molecular dynamics simulations (2017) ***Journal of Enzyme Inhibition and Medicinal Chemistry***, 32 (1), pp. 84-98.

98. Zengin Kurt, B., Sonmez, F., **Durdagi, S.,** Aksoydan, B., Ekhteiari Salmas, R., Angeli, A., Kucukislamoglu, M., Supuran, C.T. Synthesis, biological activity and multiscale molecular modeling studies for coumaryl-carboxamide derivatives as selective carbonic anhydrase IX inhibitors (2017) ***Journal of Enzyme Inhibition and Medicinal Chemistry*,** 32 (1), pp. 1042-1052.

99. Kayık, G., Tüzün, N.Ş., **Durdagi, S**. Investigation of PDE5/PDE6 and PDE5/PDE11 selective potent tadalafil-like PDE5 inhibitors using combination of molecular modeling approaches, molecular fingerprint-based virtual screening protocols and structure-based pharmacophore development (2017) ***Journal of Enzyme Inhibition and Medicinal Chemistry*,** 32 (1), pp. 311-330.

100. Kurt, B.Z., Gazioglu, I., Dag, A., Salmas, R.E., Kayık, G., **Durdagi, S.,** Sonmez, F. Synthesis, anticholinesterase activity and molecular modeling study of novel carbamate-substituted thymol/carvacrol derivatives (2017) ***Bioorganic and Medicinal Chemistry***, 25 (4), pp. 1352-1363.

101. Bukiya, AN, **Durdagi, S,** Noskov, S, Rosenhouse-Dantsker, A. Cholesterol up-regulates neuronal G protein-gated inwardly rectifying potassium (GIRK) channel activity in the hippocampus (2017). ***Journal of Biological Chemistry*** 292(15), pp6135-6147.

102. Kocak, R., Akın, E.T., Kalın, P., Talaz, O., Saracoglu, N., Dastan, A., Gülcin, I., **Durdagi, S.** Synthesis of Some Novel Norbornene-Fused Pyridazines as Potent Inhibitors of Carbonic Anhydrase and Acetylcholinesterase (2016) ***Journal of Heterocyclic Chemistry***, 53 (6), pp. 2049-2056.

103. Şahin, A., Şentürk, M., Salmas, R.E., **Durdagi, S.,** Ayan, A., Karagölge, A., Mestanoğlu, M. Investigation of inhibition of human glucose 6-phosphate dehydrogenase by some 99mTc chelators by in silico and in vitro methods (2016) ***Journal of Enzyme Inhibition and Medicinal Chemistry***, 31, pp. 141-147.

104. Salmas, R.E., Mestanoglu, M., Unlu, A., Yurtsever, M., **Durdagi, S.** Mutated form (G52E) of inactive diphtheria toxin CRM197: molecular simulations clearly display effect of the

mutation to NAD binding (2016) ***Journal of Biomolecular Structure and Dynamics*****,** 34 (11), pp. 2462-2468.

105. **Durdagi, S.,** Korkmaz, N., Işık, S., Vullo, D., Astley, D., Ekinci, D., Salmas, R.E., Senturk, M., Supuran, C.T. Kinetic and docking studies of cytosolic/tumor-associated carbonic anhydrase isozymes I, II and IX with some hydroxylic compounds (2016) ***Journal of Enzyme Inhibition and Medicinal Chemistry*****,** 31 (6), pp. 1214-1220.

106. Shityakov, S., Salmas, R.E., **Durdagi, S.,** Salvador, E., Pápai, K., Yáñez-Gascón, M.J., Pérez-Sánchez, H., Puskás, I., Roewer, N., Förster, C., Broscheit, J.-A. Characterization, in Vivo Evaluation, and Molecular Modeling of Different Propofol-Cyclodextrin Complexes to Assess Their Drug Delivery Potential at the Blood-Brain Barrier Level (2016) ***Journal of Chemical Information and Modeling***, 56 (10), pp. 1914-1922.

107. Wang, Y., Guo, J., Perissinotti, L.L., Lees-Miller, J., Teng, G., **Durdagi, S.,** Duff, H.J., Noskov, S.Y. Role of the pH in state-dependent blockade of hERG currents (2016) ***Scientific Reports***, 6, DOI: 10.1038/srep32536

108. Salmas, R.E., Yurtsever, M., **Durdagi, S.** Protein engineering studies for C-C chemokine receptor type 2 (CCR2) (2016) ***Current Enzyme Inhibition***, 12 (2), pp. 110-114.

109. Özgeris,, B., Göksu, S., Polat Köse, L., Gülçin, I., Salmas, R.E., **Durdagi, S.,** Tümer, F., Supuran, C.T. Acetylcholinesterase and carbonic anhydrase inhibitory properties of novel urea and sulfamide derivatives incorporating dopaminergic 2-aminotetralin scaffolds (2016) ***Bioorganic and Medicinal Chemistry***, 24 (10), pp. 2318-2329.

110. Salmas, R.E., Senturk, M., Yurtsever, M., **Durdagi, S.** Discovering novel carbonic anhydrase type IX (CA IX) inhibitors from seven million compounds using virtual screening and in vitro analysis (2016) ***Journal of Enzyme Inhibition and Medicinal Chemistry*****,** 31 (3), pp. 425-453.

111. Mirza, S.B., Salmas, R.E., Fatmi, M.Q., **Durdagi, S.** Virtual screening of eighteen million compounds against dengue virus: Combined molecular docking and molecular dynamics simulations study (2016) ***Journal of Molecular Graphics and Modelling***, 66, pp. 99-107.

112. **Durdagi, S.,** Salmas, R.E., Stein, M., Yurtsever, M., Seeman, P. Binding Interactions of Dopamine and Apomorphine in D2High and D2Low States of Human Dopamine D2 Receptor Using Computational and Experimental Techniques (2016) ***ACS Chemical Neuroscience***, 7 (2), pp. 185-195.

113. Ekhteiari Salmas, R., Mestanoglu, M., Durdagi, S., Sentürk, M., Kaya, A.A., Kaya, E.C. Kinetic and in silico studies of hydroxy-based inhibitors of carbonic anhydrase isoforms I and II (2016) ***Journal of Enzyme Inhibition and Medicinal Chemistry***, 31 (1), pp. 31-37.

114. Salmas, R.E., Unlu, A., Yurtsever, M., Noskov, S.Y., Durdagi, S. In silico investigation of PARP-1 catalytic domains in holo and apo states for the design of high-affinity PARP-1 inhibitors (2016) ***Journal of Enzyme Inhibition and Medicinal Chemistry*****,** 31 (1), pp. 112-120.

115. Kellici, T.F., Ntountaniotis, D., Kritsi, E., Zervou, M., Zoumpoulakis, P., Potamitis, C., **Durdagi, S**., Salmas, R.E., Ergun, G., Gokdemir, E., Halabalaki, M., Gerothanassis, I.P., Liapakis, G., Tzakos, A.G., Mavromoustakos, T. Leveraging NMR and X-ray data of the free ligands to build better drugs targeting angiotensin II Type 1 G-Protein coupled receptor (2016) ***Current Medicinal Chemistry***, 23 (1), pp. 36-59.

116. Strom, T.A., **Durdagi, S**., Ersoz, S.S., Salmas, R.E., Supuran, C.T., Barron, A.R. Fullerene-based inhibitors of HIV-1 protease (2015) ***Journal of Peptide Science***, 21 (12), pp. 862-870.

117. Salmas, RE., Yurtsever, M., Stein, M, **Durdagi, S.** Modeling and protein engineering studies of active and inactive states of human dopamine D2 receptor (D2R) and investigation of drug/receptor interactions (2015) ***Molecular Diversity*** 19(2), pp. 321-332.

118. Akincioglu, A.F., Akincioglu, H., Gulcin, I., **Durdagi, S**., Supuran, CT., Goksu, S., Discovery of potent carbonic anhydrase and acetylcholine esterase inhibitors: Novel sulfamoylcarbamates and sulfamides derived from acetophenones (2015) ***Bioorganic and Medicinal Chemistry*** 23(13) 3592-3602.

119. Fidan, I., Salmas, R.E., Arslan, M., Şentürk, M., **Durdagi, S**., Ekinci, D., Şentürk, E., Coşgun, S., Supuran, C.T. Carbonic anhydrase inhibitors: Design, synthesis, kinetic, docking and molecular dynamics analysis of novel glycine and phenylalanine sulfonamide derivatives (2015) ***Bioorganic and Medicinal Chemistry***, 23 (23), pp. 7353-7358.

120. Işik, S., Vullo, D., **Durdagi, S.,** Ekinci, D., Şentürk, M., Çetin, A., Şentürk, E., Supuran, C.T. Interaction of carbonic anhydrase isozymes I, II, and IX with some pyridine and phenol hydrazinecarbothioamide derivatives (2015) ***Bioorganic and Medicinal Chemistry Letters*****,** 25 (23), pp. 5636-5641.

121. Guo, JQ, Cheng, YM, Lees-Miller, JP, Perissinotti, LL, Claydon, TW, Hull, CM, Thouta, S, Roach, DE, **Durdagi, S**, Noskov, SY, Duff, HJ. NS1643 Interacts around L529 of hERG to Alter Voltage Sensor Movement on the Path to Activation (2015) ***Biophysical Journal*** 108(6), 1400-1413.

122. Salmas, R.E., Mestanoglu, M., Yurtsever, M., Noskov, S.Y., **Durdagi, S.** Molecular Simulations of Solved Co-crystallized X-Ray Structures Identify Action Mechanisms of PDEδ Inhibitors (2015). ***Biophysical Journal*****,** 109(6), pp. 1163-1168.

123. Salmas, RE, Yurtsever, M., **Durdagi, S.** Investigation of Inhibition Mechanism of Chemokine Receptor CCR5 by Micro-second Molecular Dynamics Simulations (2015) ***Scientific Research****,* 5, 13180, DOI: 10.1038/srep13180

124. Guo, J., **Durdagi, S**., Changalov, M., Perissinotti, L.L., Hargreaves, J.M., Back, T.G., Noskov, S.Y., Duff, H.J. Structure driven design of novel human Ether-A-Go-Go-Related-Gene channel (hERG1) activators (2014) ***PLoS ONE*****,** 9 (9), DOI:10.1371/journal.pone.0105553.

125. Leonis, G., Avramopoulos, A., Salmas, R.E., **Durdagi, S**., Yurtsever, M., Papadopoulos, M.G. Elucidation of conformational states, dynamics, and mechanism of binding in human κ-opioid receptor complexes (2014) ***Journal of Chemical Information and Modeling*****,** 54 (8), pp. 2294-2308.

126. Kufareva, I., Katritch, V., Biggin, P., Kim, M., Park, K., Jung, S.W., Cho, A.E., Sands, Z.A., Ostopovici-Halip, L., Bologa, C.G., Norn, C., Brylinski, M., Skolnick, J., Keränen, H., Lenselink, B.E., Van Westen, G., Overington, J.P., De Teráán, H.G., Isberg, V., Fidom, K.M., Lehto, T.M., Gloriam, D.E., Ghosh, A., Sonavane, U., Joshi, R., Xia, J., Hsieh, J.-H., Zhang, L., Wang, X.S., Vogel, H., Yuan, S., Feng, X., Chen, M., Ambia, J., Barth, P., Gageat, C., Stepniewski, M., Xhaard, H., Kelm, S., Pitt, W.R., Shi, J., Larsen, A., Li, H., Wagner, J., Bhattacharya, S., Vaidehi, N., Kanou, K., Cvicek, V., Kim, S.-K., Trzaskowski, B., Goddard, W.A.,III, Abrol, R., Selvam, B., Tikhonova, I.G., Cuzzolin, A., Sabbadin, D., Ciancetta, A., Moro, S., Freyd, T., Gabrielsen, M., Kristiansen, K., Sylte, I., Gaffney, K.J., Petasis, N.A., Latek, D., Bajda, M., Młynarczyk, K., Filipek, S., López, L., Kuiper, M.,

Beuming, T., Perez-Aguilar, J.M., Wang, R.Y.-R., Park, H., Greisen, P., Jr., Song, Y., DiMaio, F., Baker, D., Shin, W.-H., Heo, L., Lee, G.R., Seok, C., Yang, J., Zhang, Y., Ponassi, M., Rosano, C., Cheremovskiy, G., Grudinin, S., Chaudhari, R., Heim, A.J., Li, Z., Lv, Q., Grigorov, M.G., Hu, X., Sun, H., Shen, M., Southall, N., Jadhav, A., Rodríguez, D., Ranganathan, A., Carlsson, J., Najmanovich, R., **Durdagi, S**., De March, C., Diharce, J., Golebiowski, J., Antonczak, S., Fiorucci, S., Nguyen, E., Meiler, J., Gutcaits, A., Marti-Solano, M., Pastor, M., Selent, J., Stevens, R.C., Abagyan, R., Participants of GPCR Dock 2013 Advances in GPCR modeling evaluated by the GPCR Dock 2013 assessment: Meeting new challenges (2014) ***Structure***, 22 (8), pp. 1120-1139.

127. **Durdagi, S**., Randall, T., Duff, H.J., Chamberlin, A., Noskov, S.Y. Rehabilitating drug-induced long-QT promoters: In-silico design of hERG-neutral cisapride analogues with retained pharmacological activity (2014) ***BMC Pharmacology and Toxicology***, 15 (1), DOI: 10.1186/2050-6511-15-14

128. Göksu, S., Naderi, A., Akbaba, Y., Kalin, P., Akincioğlu, A., Gül.in, I., **Durdagi, S**., Salmas, R.E. Carbonic anhydrase inhibitory properties of novel benzylsulfamides using molecular modeling and experimental studies (2014) ***Bioorganic Chemistry*****,** 56, pp. 75-82.

129. **Durdagi, S**., Scozzafava, G., Vullo, D., Sahin, H., Kolayli, S., Supuran, C.T. Inhibition of mammalian carbonic anhydrases I-XIV with grayanotoxin III: Solution and in silico studies (2014) ***Journal of Enzyme Inhibition and Medicinal Chemistry***, 29 (4), pp. 469-475.

130. Buturak, B., **Durdagi, S**., Noskov, S.Y., Ildeniz, A.T.O. Designing of multitargeted molecules using combination of molecular screening and in silico drug cardiotoxicity prediction approaches (2014) ***Journal of Molecular Graphics and Modelling*****,** 50, pp. 16-34.

131. Zervou, M., Cournia, Z., Potamitis, C., Patargias, G., **Durdagi, S**., Grdadolnik, S.G., Mavromoustakos, T. Insights into the molecular basis of action of the AT1 antagonist losartan using a combined NMR spectroscopy and computational approach (2014) ***Biochimica et Biophysica Acta - Biomembranes***, 1838 (3), pp. 1031-1046.

132. Mavromoustakos, T., Agelis, G., **Durdagi, S**. AT1 antagonists: A patent review (2008 - 2012) (2013) ***Expert Opinion on Therapeutic Patents*****,** 23 (11), pp. 1483-1494.

133. Rosenhouse-Dantsker, A., Noskov, S., **Durdagi, S**., Logothetis, D.E., Levitan, I. Identification of novel cholesterol-binding regions in Kir2 channels (2013) ***Journal of Biological Chemistry***, 288 (43), pp. 31154-31164.

134. Kritsi, E., Potamitis, C., **Durdagi, S**., Zoumpoulakis, P., Golic Grdadolnik, S., Mavromoustakos, T. Molecular insights into the AT1 antagonism based on biophysical and in silico studies of telmisartan (2013) ***Medicinal Chemistry Research*****,** 22 (10), pp. 4842-4857.

135. Ekinci, D., Fidan, I., **Durdagi, S**., Kaban, Ş., Supuran, C.T. Kinetic and in silico analysis of thiazolidin-based inhibitors of α-carbonic anhydrase isoenzymes (2013) ***Journal of Enzyme Inhibition and Medicinal Chemistry***, 28 (2), pp. 370-374.

136. Talaz, O., Çavdar, H., **Durdagi, S**., Azak, H., Ekinci, D. Synthesis of 1,4-bis(indolin-1-ylmethyl)benzene derivatives and their structure-activity relationships for the interaction of human carbonic anhydrase isoforms i and II (2013) ***Bioorganic and Medicinal Chemistry***, 21 (6), pp. 1477-1482.

137. **Durdagi, S**., Deshpande, S., Duff, H.J., Noskov, S.Y. Modeling of open, closed, and open-inactivated states of the hERG1 channel: Structural mechanisms of the state-dependent drug binding (2012) ***Journal of Chemical Information and Modeling*****,** 52 (10), pp. 2760-2774.

138. Agelis, G., Resvani, A., **Durdagi, S**., Spyridaki, K., Tůmová, T., Slaninová, J., Giannopoulos, P., Vlahakos, D., Liapakis, G., Mavromoustakos, T., Matsoukas, J. The discovery of new potent non-peptide Angiotensin II AT1 receptor blockers: A concise synthesis, molecular docking studies and biological evaluation of Nsubstituted 5-butylimidazole derivatives (2012) ***European Journal of Medicinal Chemistry***, 55, pp. 358-374.

139. **Durdagi, S**., Guo, J., Lees-Miller, J.P., Noskov, S.Y., Duff, H.J. Structure-guided topographic mapping and mutagenesis to elucidate binding sites for the human ether-a-go-go-related gene 1 potassium channel (KCNH2) activator NS1643 (2012) ***Journal of Pharmacology and Experimental Therapeutics***, 342 (2), pp. 441-452.

140. Balaydin, H.T., **Durdağı, S**., Ekinci, D., Şentürk, M., Göksu, S., Menzek, A. Inhibition of human carbonic anhydrase isozymes I, II and VI with a series of bisphenol, methoxy and bromophenol compounds (2012) ***Journal of Enzyme Inhibition and Medicinal Chemistry*****,** 27 (4), pp. 467-475.

141. **Durdagi, S**., Vullo, D., Pan, P., Kähkönen, N., Määttä, J.A., Hytönen, V.P., Scozzafava, A., Parkkila, S., Supuran, C.T. Protein-protein interactions: Inhibition of mammalian carbonic anhydrases I-XV by the murine inhibitor of carbonic anhydrase and other members of the transferrin family (2012) ***Journal of Medicinal Chemistry***, 55 (11), pp. 5529-5535.

142. Ekinci, D., Avdar, H., **Durdagi, S**., Talaz, O., Şentürk, M., Supuran, C.T. Structure-activity relationships for the interaction of 5,10-dihydroindeno[1,2-b]indole derivatives with human and bovine carbonic anhydrase isoforms I, II, III, IV and VI (2012) ***European Journal of Medicinal Chemistry***, 49, pp. 68-73.

143. Tzoupis, H., Avramopoulos, A., Reis, H., Leonis, G., **Durdagi, S**., Mavromoustakos, T., Megariotis, G., Papadopoulos, M.G. Theoretical studies of interactions in nanomaterials and biological systems (2012) ***RSC Nanoscience and Nanotechnology*****,** pp. 148-185.

144. **Durdagi, S**., Papadopoulos, M.G., Mavromoustakos, T. An effort to discover the preferred conformation of the potent AMG3 cannabinoid analog when reaching the active sites of the cannabinoid receptors (2012) ***European Journal of Medicinal Chemistry*****,** 47 (1), pp. 44-51.

145. Tzoupis, H., Leonis, G., **Durdagi, S**., Mouchlis, V., Mavromoustakos, T., Papadopoulos, M.G. Binding of novel fullerene inhibitors to HIV-1 protease: Insight through molecular dynamics and molecular mechanics Poisson-Boltzmann surface area calculations (2011) ***Journal of Computer-Aided Molecular Design***, 25(10), pp. 959-976.

146. Akmak, R., **Durdagi, S.,** Ekinci, D., Entürk, M., Topal, G. Design, synthesis and biological evaluation of novel nitroaromatic compounds as potent glutathione reductase inhibitors (2011) ***Bioorganic and Medicinal Chemistry Letters*****,** 21 (18), pp. 5398-5402.

147. Koukoulitsa, C., **Durdagi, S**., Siapi, E., Villalonga-Barber, C., Alexi, X., Steele, B.R., Micha-Screttas, M., Alexis, M.N., Tsantili-Kakoulidou, A., Mavromoustakos, T. Comparison of thermal effects of stilbenoid analogs in lipid bilayers using differential scanning calorimetry and molecular dynamics: Correlation of thermal effects and topographical position with antioxidant activity (2011) European Biophysics Journal, 40 (7), pp. 865-875.]Durdagi, S., Zhao, C., Cuervo, J.E., Noskov, S.Y. Atomistic models for free

energy evaluation of drug binding to membrane proteins (2011) ***Current Medicinal Chemistry,*** 18 (17), pp. 2601-2611.

148. Mavromoustakos, T., **Durdagi, S**., Koukoulitsa, C., Simcic, M., Papadopoulos, M.G., Hodoscek, M., Grdadolnik, S.G. Strategies in the rational drug design (2011) ***Current Medicinal Chemistry*****,** 18 (17), pp. 2517-2530.

149. Mavromoustakos, T., Chatzigeorgiou, P., Koukoulitsa, C., **Durdagi, S**. Partial interdigitation of lipid bilayers (2011) ***International Journal of Quantum Chemistry***, 111 (6), pp. 1172-1183.

150. **Durdagi, S**., Duff, H.J., Noskov, S.Y. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain (2011) ***Journal of Chemical Information and Modeling***, 51 (2), pp. 463-474.

151. **Durdagi, S**., Entürk, M., Ekinci, D., Balaydin, H.T., Göksu, S., Küfreviolu, O.I., Innocenti, A., Scozzafava, A., Supuran, C.T. Kinetic and docking studies of phenol-based inhibitors of carbonic anhydrase isoforms I, II, IX and XII evidence a new binding mode within the enzyme active site (2011) ***Bioorganic and Medicinal Chemistry***, 19 (4), pp. 1381-1389.

152. **Durdagi, S.**, Noskov, S.Y. Mechanism of K+/Na+ selectivity in potassium channels from the perspective of the non-selective bacterial channel NaK (2011) ***Channels*****,** 5 (3), DOI: 10.4161/chan.5.3.15873

153. Politi, A., **Durdagi, S**., Moutevelis-Minakakis, P., Kokotos, G., Mavromoustakos, T. Development of accurate binding affinity predictions of novel renin inhibitors through molecular docking studies (2010) ***Journal of Molecular Graphics and Modelling*****,** 29 (3), pp. 425-435.

154. Subbotina, J., Yarov-Yarovoy, V., Lees-Miller, J., **Durdagi, S**., Guo, J., Duff, H.J., Noskov, S.Y. Structural refinement of the hERG1 pore and voltage-sensing domains with ROSETTA-membrane and molecular dynamics simulations (2010) ***Proteins: Structure, Function and Bioinformatics***, 78 (14), pp. 2922-2934.

155. **Durdagi, S**., Subbotina, J., Lees-Mille, J., Guo, J., Duff, H.J., Noskov, S.Y. Insights into the molecular mechanism of hERG1 channel activation and blockade by drugs (2010) ***Current Medicinal Chemistry***, 17 (30), pp. 3514-3532.

156. Agelis, G., Roumelioti, P., Resvani, A., **Durdagi, S.**, Androutsou, M.-E., Kelaidonis, K., Vlahakos, D., Mavromoustakos, T., Matsoukas, J. An efficient synthesis of a rationally designed 1,5 disubstituted imidazole AT1 Angiotensin II receptor antagonist: Reorientation of imidazole pharmacophore groups in losartan reserves high receptor affinity and confirms docking studies (2010) ***Journal of Computer-Aided Molecular Design***, 24 (9), pp. 749-758.

157. **Durdagi, S**., Papadopoulos, M.G., Zoumpoulakis, P.G., Koukoulitsa, C., Mavromoustakos, T. A computational study on cannabinoid receptors and potent bioactive cannabinoid ligands: Homology modeling, docking, de novo drug design and molecular dynamics analysis (2010) ***Molecular Diversity***, 14 (2), pp. 257-276.

158. Innocenti, A., **Durdagi, S**., Doostdar, N., Amanda Strom, T., Barron, A.R., Supuran, C.T. Nanoscale enzyme inhibitors: Fullerenes inhibit carbonic anhydrase by occluding the active site entrance (2010) ***Bioorganic and Medicinal Chemistry*****,** 18 (8), pp. 2822-2828.

159. Fotakis, C., Gega, S., Siapi, E., Potamitis, C., Viras, K., Moutevelis-Minakakis, P., Kokotos, C.G., **Durdagi, S**., Grdadolnik, S.G., Sartori, B., Rappolt, M., Mavromoustakos, T. Interactions at the bilayer interface and receptor site induced by the novel synthetic

pyrrolidinone analog MMK3 (2010) ***Biochimica et Biophysica Acta - Biomembranes*****,** 1798 (3), pp. 422-432.

160. Politi, A., **Durdagi, S**., Moutevelis-Minakakis, P., Kokotos, G., Papadopoulos, M.G., Mavromoustakos, T. Application of 3D QSAR CoMFA/CoMSIA and in silico docking studies on novel renin inhibitors against cardiovascular diseases (2009) ***European Journal of Medicinal Chemistry,*** 44 (9), pp. 3703-3711.

161. **Durdagi, S**., Supuran, C.T., Strom, T.A., Doostdar, N., Kumar, M.K., Barron, A.R., Mavromoustakos, T., Papadopoulos, M.G. In Silico drug screening approach for the design of magic bullets: A successful example with anti-HIV fullerene derivatized amino acids (2009) ***Journal of Chemical Information and Modeling***, 49(5), pp. 1139-1143.

162. Potamitis, C., Zervou, M., Katsiaras, V., Zoumpoulakis, P., **Durdagi, S.,** Papadopoulos, M.G., Hayes, J.M., Grdadolnik, S.G., Kyrikou, I., Argyropoulos, D., Vatougia, G., Mavromoustakos, T. Antihypertensive drug valsartan in solution and at the AT1 receptor: Conformational analysis, dynamic NMR spectroscopy, in silico docking, and molecular dynamics simulations (2009) ***Journal of Chemical Information and Modeling*****,** 49 (3), pp. 726-739.

163. **Durdagi, S**., Mavromoustakos, T., Chronakis, N., Papadopoulos, M.G. Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: Analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulations (2008) ***Bioorganic and Medicinal Chemistry,*** 16 (23), pp. 9957-9974.

164. **Durdagi, S**., Mavromoustakos, T., Papadopoulos, M.G. 3D QSAR CoMFA/CoMSIA, molecular docking and molecular dynamics studies of fullerene-based HIV-1 PR inhibitors (2008) ***Bioorganic and Medicinal Chemistry Letters*****,** 18 (23), pp. 6283-6289.

165. Kapou, A., Benetis, N.-P., **Durdagi, S**., Nikolaropoulos, S., Mavromoustakos, T. 3D QSAR/CoMFA and CoMSIA studies on antileukemic steroidal esters coupled with conformationally flexible nitrogen mustards (2008) ***Journal of Chemical Information and Modeling***, 48 (11), pp. 2254-2264.

166. **Durdagi, S**., Reis, H., Papadopoulos, M.G., Mavromoustakos, T. Comparative molecular dynamics simulations of the potent synthetic classical cannabinoid igand AMG3 in solution and at binding site of the CB1 and CB2 receptors (2008) ***Bioorganic and Medicinal Chemistry,*** 16 (15), pp. 7377-7387.

167. **Durdagi, S.**, Papadopoulos, M.G., Papahatjis, D.P., Mavromoustakos, T. Combined 3D QSAR and molecular docking studies to reveal novel cannabinoid ligands with optimum binding activity (2007) ***Bioorganic and Medicinal Chemistry Letters*****,** 17 (24), pp. 6754-6763.

168. **Durdagi, S**., Kapou, A., Kourouli, T., Andreou, T., Nikas, S.P., Nahmias, V.R., Papahatjis, D.P., Papadopoulos, M.G., Mavromoustakos, T. The application of 3DQSAR studies for novel cannabinoid ligands substituted at the C1′ position of the alkyl side chain on the structural requirements for binding to cannabinoid receptors CB1 and CB2 (2007) *Journal of Medicinal Chemistry*, 50 (12), pp. 2875-2885.

169. Salzner, U., Karalti, O., **Durdağı, S**. Does the donor-acceptor concept work for designing synthetic metals? III. Theoretical investigation of copolymers between quinoid acceptors and aromatic donors (2006) ***Journal of Molecular Modeling***, 12(5), pp. 687-701.

170. **Durdagi, S.**, Hofer, T.S., Randolf, B.R., Rode, B.M. Structural and dynamical properties of Bi3+ in water (2005) ***Chemical Physics L*etters,** 406 (1-3), pp. 20-23.

7.2. Uluslararası diğer hakemli dergilerde yayınlanan makaleler

1. Mavromoustakos, T., Tzakos, AG, **Durdagi, S.** Supramolecules in Drug Discovery and Drug Delivery Methods and Protocols, Preface (2021). 2207, V.

2. Iqbal, J., Al-Rashida, M., **Durdagi, S**., Alterio, V., Di Fiore, A. Recent Developments of Carbonic Anhydrase Inhibitors as Potential Drugs (2015) DOI: 10.1155/2015/174178

3. **Durdagi, S**, Noskov, SY. Mechanism of K+/Na+ selectivity in potassium channels from the perspective of the non-selective bacterial channel NaK (2011) Channels, 5(3), 198-200.

7.3. Uluslararası bilimsel toplantılarda sunulan ve bildiri kitabında (*Proceedings*) basılan bildiriler

1. Kanan, D**.,** Kanan, T**.,** Dogan, B**., Durdagi, S.** Discovery of promising antineoplastic drugs against the USP7 deubiquitinating enzyme: A pharmacophore-based FDA-approved and investigational drugs repurposing study (2021). *Cancer Research* 81(13), meeting abstract: 277.

2. **Durdagi, S.** An Integrated Computational Approach for the Discovery of Ubiquitin Specific Protease 7 (USP7) Inhibitors as Potential Cancer Therapies (2021) *Biophysical Journal,* 118(3), 47a.

3. Cavusoglu, K., Senturk, M., **Durdagi, S**. Determination of in Vitro and in Silico Effects of Some Uracil Derivatives on Carbonic Anhydrase I Isoenzyme (2020) *Acta Physiologica* 227, 122.

4. Onder, FC., Ay, M., **Durdagi, S**., Ozpolat, B., Kantarcioglu, I. New and potent small molecule as EF2K inhibitor: A novel EF2K inhibitor (2019) *Cancer Research* 79(13), 4787.

5. Sahaboglu, A., Miranda, M., **Durdagi, S,** Kayik, G., Zrenner, E. PARP inhibitors: The protective ways on retinal degeneration (2019) *Investigative Ophtalmology and Visual Science* 60(9), 5177.

6. **Durdagi, S**., Erol, I., Dogan, B., Sen, TB. Integration of Text Mining and Binary QSAR Models for Novel Anti-Hypertensive Antagonist Scaffolds (2019) *Biophysical Journal* 116(3) 478a.

7. Zervou, M., Cournia, Z., Potamitis, C., Patargias, G., **Durdagi, S.,** Grdadolnik, SG., Mavromoustakos, T. Molecular basis of action of the AT1 antagonist losartan (2015) *Abstracts of Papers of the American Chemical Society.* 247, 67-COMP.

8. **Durdagi, S.,** Patterson, M**.,** Noskov, SY**.** Development and Validation Studies of Universal Pharmacophore Models for hERG Channel Openers (2014) *Biophysical Journal* 106(2), 15a.

9. Rosenhouse-Dantsker, A., Noskov, S., **Durdagi, S**., Logothetis, DE., Levitan, I. Identification of Novel Cholesterol Binding Regions in the Transmembrane Domain of Kir2.1 (2014) *Biophysical Journal* 106(2) 747a.

10. **Durdagi, S**., Randal, T. , Duff, HJ., Noskov, SY. Rehabilitation Studies for withdrawn Drugs from the Market: Derivation of Non-hERG1 Channel Blocker Cisapride Analogues using Multi-Faceted Approaches (2013) *Biophysical Journal* 104(2), 266a

11. **Durdagi, S.,** Deshpande, S., Duff, H., Noskov, S. Development of Atomistic Models for Closed, Open and Open-Inactivated States of hERG1 Channel using Rosetta Protein Modeling Suite and Molecular Dynamics Simulations (2012) *Biophysical Journal,* 102(3) 679a.

12. **Durdagi, S.,** Noskov, SY. Consistency of constructed hERG1 pore domain and pharmacophore models: A 3D-QSAR, molecular docking, and pharmacophore modeling study (2011) *Biochemistry and Cell Biology* 89(2) 266-267.

13. **Durdagi, S.,** Koukoulitsa, C, Kapou, A, Kourouli, T, Andreou, T, Nikas, SP, Nahmias, VR, Papahatjis, DP, Papadopoulos, MG, Mavromoustakos, T. Testing the 3D QSAR/ComFA-CoMSIA results of flexible bioactive compounds with molecular docking studies (2007) *Drugs of the Future* 32, 79.

14. Mavromoustakos, T, Zervou, M, Zoumpoulakis, P, Potamitis, C, Katsiaras, V, Politi, A, Mantzourani, E, **Durdagi, S**, Koukoulitsa, C. Putative bioactive conformers of small molecules: A concerted approach using NMR spectroscopy and computational chemistry (2007) *Drugs of the Future* 32, 33.

7.4. Yazılan uluslararası kitaplar veya kitaplarda bölümler

1. Mavromoustakos, T., Tzakos, A.G., **Durdagi, S**. Supramolecules in Drug Discovery and Drug Delivery. Springer, 2021.

2. Kiriakidi, S., Kolocouris, A., Liapakis, G., Ikram, S., **Durdagi, S.**, Mavromoustakos, T., RosenhouseDantsker, A., Bukiya, AN. Effects of Cholesterol on GPCR Function: Insights from Computational and Experimental Studies (2019) Direct Mechanisms in Cholesterol Modulation of Protein Function, *Advances in Experimental Medicine and Biology* 1135, 89-103.

3. Erol, I., Aksoydan, B., Kantarcioglu, I, **Durdagi, S**., Mavromoustakos, T., Kellici, TF. Application of Multiscale Simulation Tools on GPCRs. An Example with Angiotensin II Type 1 Receptor (2019) Rational Drug Design: Methods and Protocols, *Methods in Molecular Biology*. 1824, 431-448.

4. Tzoupis, H., Avramopoulos, A., Reis, H., Leonis, G., **Durdagi, S**., Mavromoustakos, T., Megariotis, G., Papadopoulos, MG. Theoretical Studies of Interactions in Nanomaterials and Biological Systems (2013) Towards Efficient Designing of Safe Nanomaterials: Innovative Merge of Computational Approaches and Experimental Techniques. *RSC Nanoscience and Nanotechnology* 25, 148-185.

5. **Durdagi S.** Recent Advances in Computational Drug Design Studies: The Application of In Silico Methodologies for Bioactive Cannabinoid and Fullerene Derivatives (2010), VDM-Verlag.

6. Mavromoustakos, T.; Golic Grdadolnik, S.; Zervou, M.; Zoumpoulakis, P.; Potamitis, C.; Politi, A.; Mantzourani, E.; Platts, J.A.; Koukoulitsa, C.; Minakakis, P.; Kokotos, G.; Tselios, T.; Matsoukas, J.; **Durdagi, S**.; Papadopoulos, M. G.; Papahatjis, D.P.; Spyranti, Z.S.; Dalkas, G.A.; Spyroulias, G.A. *Medicinal Chemistry Research Progress,* "Putative Bioactive Conformers of Small Molecules: A Concerted Approach Using NMR Spectroscopy and Computational Chemistry", 175-205, Colombo, G. P.; Ricci, S. (Ed.) 2009.

7. Salzner, U.; Karalti, O.; **Durdagi, S**, Clark, T. Highlights in Computational Chemistry II. "Does the Donor–Acceptor Concept Work for Designing Synthetic Metals? Theoretical Investigation of Copolymers between Quinoid Acceptors and Aromatic Donors", 687-702, 2006.

7.5. Ulusal hakemli dergilerde yayınlanan makaleler

1. Unver, Y., Unluer, D., Direkel, S., **Durdagi, S.** Bis benzothiophene schiff bases: Synthesis and in silico-guided biological activity studies (2020) *Turkish Journal of Chemistry*, 44 (4), pp. 1164-1176.

2. Şahin, K., **Durdağı, S**. Identifying the novel pyrimidine-based cdk2 inhibitors as anticancer agents using text-mining and combined molecular modeling approaches (2020) *Journal of the Turkish Chemical Society, Section A: Chemistry*, 7 (2), pp. 383-404.

3. **Durdağı, S**. Virtual drug repurposing study against SARS-CoV-2 TMPRSS2 target (2020) *Turkish Journal of Biology*, 44 (Special issue 1), pp. 185-191.

4. Sahin, K., **Durdagi, S.** Combined ligand and structure-based virtual screening approaches for identification of novel ache inhibitors (2020) *Turkish Journal of Chemistry*, 44 (3), pp. 574-588.

7.6. Ulusal bilimsel toplantılarda sunulan ve bildiri kitabında basılan bildiriler

1. **Durdagi, S.** 3. Ilac Kimyasi Kongresi "Uzun Moleküler Dinamik Simülasyonlar ile hERG İyon Kanal Açıcılarının Kanal Bağlanma Bölgelerinde Dinamik ve Yapısal Etkilerinin İncelenmesi ve Yeni hERG Kanal Açıcılarının Keşfi" Antalya, 2015.

2. **Durdagi, S**.; Patterson, M.; Noskov, S.Y. 2. Ilac Kimyasi Kongresi "hERG Iyon Kanali Acicilarinin Tasarimi icin Genel Farmakofor Modellerin Gelistirilmesi ve Validasyon Calismalari" Antalya, 2014.

3. **Durdagi, S**.; Guo, J.; Changalov, M.; Perissinotti, LL.; Hargreaves, J.M.; Back, T.M.; Noskov, S.Y.; Duff, H.J. 25. Ulusal Biyofizik Kongresi "hERG1 Potasyum Kanal Agonisti NS1643 ve Turevlerinin Yapı-Fonksiyon Analizleri ve Moleküler Mühendislik Çalışmaları: Sentez, Elektrofizyoloji, Ligand ve Yapı-Bazlı İlaç Tasarım Çalışmaları Kombinasyonu" Trabzon, 2013.

4. Ekhteiari Salmas, R.; **Durdagi, S**.; Stein, M.; Yurtsever , M. 25. Ulusal Biyofizik Kongresi "Dopamin (D2) Reseptorünün Aktif ve İnaktif Konformasyonlarının Protein Modelleme Teknikleri ile Geliştirilmesi ve Validasyonu: Şizofreni Tedavisinde Kullanılan Standart İlaçların Moleküler Mekanizmalarının Aydınlatılması" Trabzon, 2013.

5. **Durdagi, S**; Duff, H.J.; Noskov, S. 25. Ulusal Kimya Kongresi "Recent Advances on Computer Aided Drug Design Studies" Erzurum, 2011

6. Şentürk, M.; Ekinci, D.; **Durdagi, S**. 25. Ulusal Kimya Kongresi "Bazı Organik Bileşikler ve Amino Asitlerin İnsan Asetilkolinesteraz ve Butirilkolinesteraz Enzimleri Üzerindeki İnhibisyon Kinetiği ve Mekanizması" Erzurum, 2011.

7. Ekinci, D.; Şentürk, M.; **Durdagi S.** International Conference on Enzyme Science and Technology "Biological activity and molecular modeling studies of some natural compounds as α and β-glycosidase inhibitors", Kuşadası, 2011

8. **Durdagi, S**.; Kaplan Can, H.; Guner, A. 15. Ulusal Kimya Kongresi "BSA'in çapraz bağlı

Dietilaminoetil mikro küreleri üzerine adsorpsiyonu" İstanbul, 2001.

7.7. Diğer yayınlar

7.8. Uluslararası atıflar

1. Kufareva vd. Structure (2013), toplam atıf sayısı: 135
2. Akincioglu vd. Bioorganic and Medicinal Chemistry (2015), toplam atıf sayısı: 124
3. Ozgeris vd. Bioorganic and Medicinal Chemistry (2016), toplam atıf sayısı: 119
4. Goksu vd. Bioorganic Chemistry (2014), toplam atıf sayısı: 102
5. Durdagi vd. Bioorganic and Medicinal Chemistry (2011), toplam atıf sayısı: 91
6. Durdagi vd. Bioorganic and Medicinal Chemistry (2008), toplam atıf sayısı: 82
7. Durdagi vd. Journal of Chemical Information and Modeling (2011), toplam atıf sayısı: 69
8. Rosenhouse-Dantsker vd. Journal of Biological Chemistry (2013), toplam atıf sayısı: 67
9. Innocenti vd. Bioorganic and Medicinal Chemistry (2010), toplam atıf sayısı: 65
10. Durdagi vd. Journal of Chemical Information and Modeling (2012), toplam atıf sayısı: 61
11. Akincioglu vd. Bioorganic Chemistry (2017), toplam atıf sayısı: 58
12. Mollica vd. Journal Of Biomolecular Structure and Dynamics (2019), toplam atıf sayısı: 57
13. Cavdar vd. Journal of Enzyme Inhibition and Medicinal Chemistry (2019), toplam atıf sayısı: 53
14. Durdagi vd. Journal of Chemical Information and Modeling (2009), toplam atıf sayısı: 53
15. Politi vd. Journal of Molecular Graphics and Modelling (2010), toplam atıf sayısı: 51
16. Durdagi vd. Bioorganic and Medicinal Chemistry Letters (2008), toplam atıf sayısı: 51
17. Ekinci vd. European Journal of Medicinal Chemistry (2012), toplam atıf sayısı: 50
18. Politi vd. European Journal of Medicinal Chemistry (2009), toplam atıf sayısı: 49
19. Salzner vd. Journal of Molecular Modeling (2006), toplam atıf sayısı: 47
20. Cakmak vd. Bioorganic and Medicinal Chemistry Letters (2011), toplam atıf sayısı: 45
21. Subbotina vd. Proteins: Structure, Function and Bioinformatics (2010), toplam atıf sayısı: 45
22. Balaydin vd. Journal of Enzyme Inhibition and Medicinal Chemistry (2012), toplam atıf sayısı: 43
23. Tzoupis vd. Journal of Computer-Aided Molecular Design (2011), toplam atıf sayısı: 43
24. Durdagi vd. Journal of Medicinal Chemistry (2007), toplam atıf sayısı: 43
25. Potamitis vd. Journal of Chemical Information and Modeling (2009), toplam atıf sayısı: 41
26. Kurt vd. Bioorganic Chemistry (2019), toplam atıf sayısı: 38
27. Kurt vd. Bioorganic and Medicinal Chemistry (2017), toplam atıf sayısı: 37
28. Salmas vd. Scientific Reports (2015), toplam atıf sayısı: 36
29. Durdagi vd. ACS Chemical Neuroscience (2016), toplam atıf sayısı: 34
30. Işık vd. Bioorganic and Medicinal Chemistry Letters (2015), toplam atıf sayısı: 34
31. Durdagi vd. Journal of Enzyme Inhibition and Medicinal Chemistry (2014), toplam atıf sayısı: 34
32. Kocak vd. Journal of Heterocyclic Chemistry (2016), toplam atıf sayısı: 33
33. Fidan vd. Bioorganic and Medicinal Chemistry (2015), toplam atıf sayısı: 33
34. Shityakov vd. Journal of Chemical Information and Modeling (2016), toplam atıf sayısı: 32
35. Mirza vd. Journal of Molecular Graphics and Modelling (2016), toplam atıf sayısı: 32
36. Zervou vd. Biochimica et Biophysica Acta – Biomembranes (2014), toplam atıf sayısı: 32
37. Salmas vd. Cell Biochemistry and Function (2017), toplam atıf sayısı: 29

38. Strom vd. Journal of Peptide Science (2015), toplam atıf sayısı: 29
39. Durdagi vd. Journal of Molecular Graphics and Modelling (2018), toplam atıf sayısı: 28
40. Durdagi vd. Molecular Diversity (2010), toplam atıf sayısı: 28
41. Durdagi vd. Bioorganic and Medicinal Chemistry Letters (2007), toplam atıf sayısı: 28
42. Bukiya vd. Journal of Biological Chemistry (2017), toplam atıf sayısı: 26
43. Guo vd. Biophysical Journal (2015), toplam atıf sayısı: 26
44. Agelis vd. European Journal of Medicinal Chemistry (2012), toplam atıf sayısı: 26
45. Wang vd. Scientific Reports (2016), toplam atıf sayısı: 25
46. Salmas vd. Molecular Diversity (2015), toplam atıf sayısı: 25
47. Durdagi vd. Journal of Pharmacology and Experimental Therapeutics (2012), toplam atıf sayısı: 25
48. Kiriakidi vd. Advances in Experimental Medicine and Biology (2019), toplam atıf sayısı: 24
49. Durdagi vd. Journal of Medicinal Chemistry (2012), toplam atıf sayısı: 24
50. Orhan vd. Phytomedicine (2018), toplam atıf sayısı: 23
51. Kurt vd., Journal of Enzyme Inhibition and Medicinal Chemistry (2017), toplam atıf sayısı: 22
52. Leonis vd. Journal of Chemical Information and Modeling (2014), toplam atıf sayısı: 22
53. Rodrigues vd. Industrial Crops and Products (2018), toplam atıf sayısı: 20
54. Shityakov vd. Journal of Molecular Structure (2017), toplam atıf sayısı: 20
55. Kayik vd., Journal of Enzyme Inhibition and Medicinal Chemistry (2017), toplam atıf sayısı: 20
56. Mavromoustakos vd. International Journal of Quantum Chemistry (2011), toplam atıf sayısı: 20
57. Kanan vd. Journal of Molecular Graphics and Modelling (2019), toplam atıf sayısı: 19
58. Mavromoustakos vd. Expert Opinion on Therapeutic Patents (2013), toplam atıf sayısı: 19
59. Koukoulitsa vd. European Biophysics Journal with Biophysics Letters (2011), toplam atıf sayısı: 19
60. Is vd. ACS Chemical Neuroscience (2018), toplam atıf sayısı: 18
61. Mirza vd. Journal of Molecular Graphics and Modelling (2018), toplam atıf sayısı: 17
62. Salmas vd. ACS Chemical Neuroscience (2017), toplam atıf sayısı: 17
63. Salmas vd. Journal of Enzyme Inhibition and Medicinal Chemistry (2016), toplam atıf sayısı: 17
64. Guo vd. PLoS ONE (2014), toplam atıf sayısı: 17
65. Durdagi vd. BMC Pharmacology and Toxicology (2014), toplam atıf sayısı: 17
66. Agelis vd. Journal of Computer-Aided Molecular Design (2010), toplam atıf sayısı: 16
67. Tutumlu vd. Frontiers in Chemistry (2020), toplam atıf sayısı: 15
68. Durdagi vd. Turkish Journal of Biology (2020), toplam atıf sayısı: 15
69. Kellici vd. Current Medicinal Chemistry (2016), toplam atıf sayısı: 15
70. Ntountaniotis vd. Molecular Pharmaceutics (2019), toplam atıf sayısı: 14
71. Durdagi vd. European Journal of Medicinal Chemistry (2018), toplam atıf sayısı: 14
72. Salmas vd. ACS Chemical Neuroscience (2017), toplam atıf sayısı: 14
73. Salmas vd. Biophysical Journal (2015), toplam atıf sayısı: 14
74. Turan vd. Scientific Reports (2020), toplam atıf sayısı: 13
75. Aksoydan vd. Journal of Molecular Graphics and Modelling (2018), toplam atıf sayısı: 13
76. Kapou vd. Journal of Chemical Information and Modeling (2008), toplam atıf sayısı: 13
77. Durdagi vd. Structure (2021), toplam atıf sayısı: 12
78. Ozten vd. Bioorganic Chemistry (2021), toplam atıf sayısı: 12
79. Gungor vd. European Journal of Medicinal Chemistry, toplam atıf sayısı: 12
80. Oguz vd. Journal of Biomolecular Structure and Dynamics (2020), toplam atıf sayısı: 12
81. Sahaboglu vd. Cellular and Molecular Life Sciences (2020), toplam atıf sayısı: 12
82. Onder vd. Journal of Chemical Information and Modeling (2020), toplam atıf sayısı: 12
83. Zaka vd. Journal of Biomolecular Structure and Dynamics (2019), toplam atıf sayısı: 12

84. Durdagi vd. Neuroscience Letter (2019), toplam atıf sayısı: 12
85. Orhan vd. Bioorganic Chemistry (2019), toplam atıf sayısı: 12
86. Salmas vd. Journal of Biomolecular Structure and Dynamics (2017), toplam atıf sayısı: 12
87. Salmas vd. Journal of Biomolecular Structure and Dynamics (2017), toplam atıf sayısı: 12
88. Ekinci vd. Journal of Enzyme Inhibition and Medicinal Chemistry (2013), toplam atıf sayısı: 12
89. Durdagi vd. Bioorganic and Medicinal Chemistry (2008), toplam atıf sayısı: 12
90. Durdagi vd. Molecular Therapy (2022), toplam atıf sayısı: 11
91. Durdagi vd. Current Opinion in Structural Biology (2019), toplam atıf sayısı: 11
92. Talaz vd. Bioorganic and Medicinal Chemistry (2013), toplam atıf sayısı: 11

*10 üzerinde atıf alan makaleler lislenmiştir. Toplam atıf sayısı: 3275, h-endeks: 33

8. Ulusal & Uluslararası Projeler

1. Targeting RNA as an approach for treating retinal disease (RETORNA), EU Horizon Europe (2023-2027), Proje yürütücüsü

2. Molekül Veri Bankalarından Yeni IL-17A İnhibitörü Moleküllerin Belirlenmesi ve Multipl Sklerozda Enflamasyonu Baskılamadaki Etkinliğinin İn in Vitro vitro ve İn in Vivo vivo Yöntemlerle Araştırılması, TÜBİTAK-1001, Araştırmacı, (2023-2025)

3. 18AG020, Ülkemizde ve Dünyada Halk Sağlığını En Fazla Tehdit Eden HIV, HPV ve Influenza Kaynaklı Enfeksiyonlara Karşı Tanı Kitleri, İlaç Formülasyonları ve Aşı Geliştirilmesi, TÜBİTAK 1004, Mükemmeliyet Merkezi Destek Programı, Araştırmacı, (2020-2022)

4. 119N234, Malign Gliomaya Karşı Makine Öğrenmeye Dayalı Yeni Anti Kanser Terapötik Moleküllerin Geliştirilmesi, TÜBİTAK Uluslararası, UPAG (2020-2022), Proje Yürütücüsü

5. Kötü famarkokinetik parametrelere sahip kullanılan ilaçların ve preklinik ve klinik safhalarda çalışılan ilaç adayı küçük moleküllerin in siliko yöntemler ile rehabilite edilerek beyin tümörlerine karşı kullanılması, TÜSEB, Proje Yürütücüsü, (2020-2022)

6. 215S008, Moleküler Modelleme Tabanlı, Kanser Tedavisine Yönelik Protein Kinaz İnhibitörlerin Tasarımı, Sentezi, Denetimli Salım Ile In Vitro Ve In Vivo Etkinliklerinin İncelenmesi, TÜBİTAK 1003, Araştırmacı (2016-2021)

7. 215S681, Metilmalonil Koenzim A Mutaz Enziminin Konformasyonel Bozukluğuna Bağlı Olarak Gelişen Metilmalonik Asidemi Hastalığında Farmakolojik Şaperon Uygulamasi İle Enzim Aktivitesinin Yeniden Kazandırılması, TÜBİTAK 1001, Araştırmacı (2017-2020)

8. 218S752, Akciğer Kanserinde İmmün Kontrol Noktası (Checkpoint) İle Çoğunluğu Algılama Sistemi (QS) Arasındaki Potansiyel İlişkinin Liken Sekonder Metabolitleriyle İnhibisyonun Araştırılması, TÜBİTAK COST, (2019-2021), Araştırmacı

9. 216S297, Parkinson Hastalığının Tedavisinde Birden Fazla Reseptörü Hedefleyebilen Özgün Terapötik Moleküllerin Geliştirilmesi, TÜBİTAK COST, (2017-2022), Araştırmacı

10. 216S885, Türk Liken Biyokaynakları Kullanılarak Bakteriyel Quorum Sensing İnhibitörü Yeni Antimikrobiyal Bileşenlerin Geliştirilmesi ve Sanayiye Aktarılması,

TÜBİTAK COST, (2017-2019), Araştırmacı

11. Dengue Virüsüne Karşı Yeni Hedeflerin Bilgisayar Destekli İlaç Tasarımı Teknikleri ile Geliştirilmesi; TÜBİTAK 2216 (Uluslararası Araştırmacılar İçin Araştırma Burs Programı). Bahçeşehir Üniversitesi, Tıp Fakültesi (2015-2016) Proje Danışmanı

12. Potasyum iyon kanalı human *ether-a-go-go-related* gene (hERG) için ligand ve yapı bazlı 3 boyutlu atomistik modellerin oluşturulması, bu modellerin validasyon çalışmalarının yapılması ve geliştirilen modellerde ligand/reseptör etkileşimlerinin teorik incelenmesi. (Kanada Sağlık Araştırmaları Enstitüsü-*Canadian Institute of Health Research (CIHR)* Araştırma Fonu (201103MOP-CSA-244888). (2011-2013) Proje Yürütücüsü

13. Nörodejeneratif hastalıklara karşı geliştirilme potansiyeli olan yeni ilaçlar için potent biyoaktif moleküllerin çeşitli ortamlarda yapı ve dinamik özelliklerinin moleküler mekanik ve kuantum mekanik teknikleri ile incelenmesi. Ulusal Yunan Araştırma Kurumu-*National Hellenic Research Foundation (NHRF)*, Avrupa Birliği 6. Çerçeve Marie-Curie Actions Araştırma Fonu (EURODESY-MEST-CT-2005-02057) (2006-2009), Marie Curie Bursiyeri

14. 214S122, Acne Vulgaris Hastalığının Etmenlerinin Propionibacterium Acnes Bakterisinin Liken Türlerinden İzole Edilen Sekonder Metabolitler Kullanılarak Biyofilm Oluşturulmasının Engellenmesi, TÜBİTAK COST, (2015-2018), Araştırmacı

15. Potasyum iyon kanallarının *in siliko* çalışılması: Modelleme, simülasyon ve yeni algoritmalar geliştirilmesi. TÜBİTAK 2236 (Uluslararası Deneyimli Araştırmacı Dolaşım Destek Programı), (2013-2015) Proje Yürütücüsü

16. 214Z122, Yeni Nesil Anti-Hipertansif Molekül Olarak Yapı-Bazlı Tasarlanan Okşazolon Ve İmidazolon Türevlerin Fizikokimyasal ve Biyolojik Özelliklerinin Moleküler Modelleme ve Biyofiziksel Yöntemler ile Araştırılması ve Hücre Proliferasyonu Üzerine Olası Kısıtlayıcı Etkilerinin Analizi; TÜBİTAK 1001 (Bilimsel ve Teknolojik Araştırma Projelerini Destekleme Programı), (2015-2018) Proje Yürütücüsü

9. İdari Görevler

1. Dekan, Bahçeşehir Üniversitesi Eczacılık Fakültesi (2022-)
2. Temel Tıp Bilimleri Bölüm Başkanı, Bahçeşehir Üniversitesi Tıp Fakültesi, (2019-2022)
3. Dekan Yrd., Bahçeşehir Üniversitesi, Tıp Fakültesi (2014 - 2018)
4. Senato Üyesi, Bahçeşehir Üniversitesi (2019-)
5. Sürekli Mesleki Gelişim Komisyonu, Bahçeşehir Üniversitesi, Tıp Fakültesi (2019-2022)
6. Ölçme Değerlendirme Kurulu Üyesi, Bahçeşehir Üniversitesi, Tıp Fakültesi (2019-2022)
7. Anabilim Dalı Başkanı, Biyofizik, Bahçeşehir Üniversitesi Tıp Fakültesi, (2014-2022)
8. Fakülte Yönetim Kurulu Üyesi, Bahçeşehir Üniversitesi, Tıp Fakültesi (2013-2022)
9. Disiplin Kurulu Üyesi, Bahçeşehir Üniversitesi, Tıp Fakültesi (2013-2022)

10. Bilimsel ve Mesleki Kuruluşlara Üyelikler

1. Kanada Biyofizik Derneği (2022 -)
2. Alman Biyofizik Derneği (2018-)
3. Türk Biyofizik Derneği (2016-)
4. Türk Kimya Derneği (2016 -)
5. Moleküler Grafik ve Modelleme Derneği- *Molecular Graphics and Modelling Society* (2013 -)
6. Amerika Biyofizik Derneği -*Biophysical Society* (2012 -)

7. Amerika Kimya Derneği- *American Chemical Society* (2012 -)
8. Kanada Kimya Derneği- *Canadian Society for Chemistry* (2012 -)

11. Ödüller

1. Bilime Katkı Ödülü, Bahçeşehir Üniversitesi (2023)
2. Topluma Katkı Ödülü, Bahçeşehir Üniversitesi (2021)
3. TÜSEB Aziz Sancar Teşvik Ödülü (2017)
4. TÜBİTAK Teşvik Ödülü (2016)
5. Bilim Akademisi BAGEP Ödülü (2014)
6. Bilime Katkı Ödülü, Bahçeşehir Üniversitesi (2016)

12. Son iki yılda verdiğiniz lisans ve lisansüstü düzeydeki dersler için aşağıdaki tabloyu doldurunuz.

Akademik Yıl	Dönem	Dersin Adı	Haftalık Saati		Öğrenci Sayısı
			Teorik	Uygulama	
2021-2022	Güz	TMED1000 (Biyofizik)	2	1	180
		MED2017 (Moleküler Modelleme ve Simülasyonlara Giriş)	2	1	12
	Bahar	TMED1000 (Biyofizik)	2	1	180
2022-2023	Güz	TMED1000 (Biyofizik)	2	1	180
		MED2043 (Antikanser İlaç Geliştirmede Makine Öğrenmesi Yöntemleri)	2	1	17
		PHAR1003 (Chemistry of Life)	3	3	26
	Bahar	TMED1000 (Biyofizik)	2	1	180
		PHAR1004 (Chemistry of Life)	3	3	30